UNIVERSAL HEALTH SERVICES INC
(UHS)CIK 352915 · SEC filings only
shown as history
Dividend record — shown as history, not graded
A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.
Dividend record
18 declarations · 0 raised · 15 held · 0 cut · held 15 quarters
- NOTED$0.2000/shperiod ended 2019-09-30Filing ↗
- HELD$0.1000/shperiod ended 2019-06-30Filing ↗
- HELD$0.1000/shperiod ended 2019-03-31Filing ↗
- HELD$0.1000/shperiod ended 2018-09-30Filing ↗
- HELD$0.1000/shperiod ended 2018-06-30Filing ↗
- HELD$0.1000/shperiod ended 2018-03-31Filing ↗
- HELD$0.1000/shperiod ended 2017-09-30Filing ↗
- HELD$0.1000/shperiod ended 2017-06-30Filing ↗
- HELD$0.1000/shperiod ended 2017-03-31Filing ↗
- HELD$0.1000/shperiod ended 2016-09-30Filing ↗
- HELD$0.1000/shperiod ended 2016-06-30Filing ↗
- HELD$0.1000/shperiod ended 2016-03-31Filing ↗
harness minimum not met
Not enough resolved promises to grade
0 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.
buyback history
Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.
See Pro →Open promises (11)
Pursuant to our $2.7 billion stock repurchase program, which had an aggregate available repurchase authorization of $559.6 million as of March 31, 2021
our Board of Directors authorized a $1.0 billion increase to our stock repurchase program, which increased the aggregate authorization to $3.7 billion
we had an aggregate stock repurchase authorization of $3.7 billion
our Board of Directors authorized a $1.4 billion increase to our stock repurchase program
our Board of Directors authorized a $1.4 billion increase to our stock repurchase program
As of September 30, 2023, we had an aggregate available repurchase authorization of approximately $580 million.
As of March 31, 2024, we had an aggregate available repurchase authorization of approximately $298 million.
our Board of Directors authorized a $1.0 billion increase to our stock repurchase program
our Board of Directors authorized a $1.0 billion increase to our stock repurchase program
As of December 31, 2024, we had an aggregate available repurchase authorization of approximately $824.4 million pursuant to our stock repurchase program.
our Board of Directors authorized a $1.5 billion increase to our stock repurchase program
grade
Sector median (Industrial Applications and Services): B+ across 28 graded companies
Resolved promises
Full say-do history
Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.
See Pro →Guidance by basis
8 of 14 guidance figures that were graded or dropped for basis could not be graded on the same basis (57%). Guidance marked “not judged” is in neither number.
| Guidance type | Said | Graded | Dropped | Other |
|---|---|---|---|---|
| Revenue · basis not stated | 13 | 6 | 0 | 7 |
| EPS · non-GAAPcannot be graded | 9 | 0 | 6 | 3 |
| EPS · basis not statedcannot be graded | 4 | 0 | 2 | 2 |
Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.
Guidance shown, not graded (13)
We show what was said — with its source filing — but never score it. The line under each statement says why.
- eps guidance fy · Jul 28, 2026Adjusted EPS – diluted $22.28 per share $23.65 per shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Feb 26, 2026EPS-diluted $22.64 per share $24.52 per shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Oct 28, 2025Adjusted EPS – diluted $21.50 per share $22.10 per shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jul 29, 2025Our revised 2025 forecasted Adjusted EPS-diluted is estimated to be $20.00 per share to $21.00 per shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Feb 27, 2025EPS-diluted $18.45 per share $19.95 per shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jul 25, 2024Our revised 2024 forecasted Adjusted EPS-diluted is estimated to be $15.40 per share to $16.20 per shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Feb 27, 2024Our EPS-diluted range is estimated to be $13.00 per diluted share to $14.00 per diluted shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jul 26, 2023Adjusted EPS – diluted $9.85 per share $10.50 per shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Feb 27, 2023Our Adjusted EPS-diluted range is estimated to be $9.50 per diluted share to $10.50 per diluted shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Feb 24, 2022Our Adjusted EPS-diluted range is estimated to be $11.90 per diluted share to $12.90 per diluted shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jul 27, 2021Our revised 2021 forecasted Adjusted EPS-diluted is estimated to be $11.46 per share to $12.16 per shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Feb 25, 2021Our Adjusted EPS-diluted range is estimated to be $10.05 per diluted share to $11.05 per diluted shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Feb 27, 2019Adjusted EPS-diluted $9.70 per share $10.40 per shareUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
Open promises (1) · 6 superseded
Net revenues $18.501 billion $18.762 billion
Net revenues $18.417 billion $18.789 billion
Our net revenues are estimated to be approximately $14.044 billion to $14.314 billion
Our net revenues are estimated to be approximately $15.411 billion to $15.706 billion
Our 2025 forecasted range of net income attributable to UHS, and EPS-diluted, exclude certain items as described below because we do not believe we can forecast those items with sufficient accuracy. Adjusted EBITDA net of NCI, is a non-GAAP financial measure and should not be considered a measure of financial performance under GAAP. We believe Adjusted EBITDA net of NCI is helpful to our investors as a measure of our operating performance. Please see the Supplemental Non-GAAP Disclosures - 2025 Operating Results Forecast schedule as included herein for additional information and a reconciliation of our 2025 forecasted range of net income attributable to UHS to our 2025 forecasted range of Adjusted EBITDA net of NCI.
Our revised 2025 forecasted net revenues are estimated to be approximately $17.096 billion to $17.312 billion
Our net revenues are estimated to be approximately $12.125 billion to $12.361 billion
Credibility timeline
Timeline as a list
- Feb 26, 2020ABOVENet revenues $11.213 billion $11.361 billion
- Feb 24, 2022ABOVEOur revised 2021 forecasted net revenues are estimated to be approximately $12.351 billion to $12.502 billion
- Feb 27, 2023BELOWOur net revenues are estimated to be approximately $13.424 billion to $13.694 billion
- Feb 27, 2024IN LINENet revenues $14.130 billion $14.330 billion
- Feb 26, 2025ABOVEOur revised 2024 forecasted net revenues are estimated to be approximately $15.565 billion to $15.753 billion
- Feb 25, 2026IN LINENet revenues $17.306 billion $17.445 billion